Low FODMAP vs traditional IBS dietary advice: the Swedish head-to-head trial

Study at a glance

Böhn and colleagues ran a multicentre, single-blind randomised trial in Swedish gastroenterology clinics comparing a four-week low FODMAP diet against “traditional” IBS dietary advice. Symptom severity fell substantially in both arms, with no meaningful difference between them: 50% of the low FODMAP group and 46% of the traditional-advice group hit the responder threshold. The trial is small and short, but it remains one of the few fair comparisons between the diet everyone talks about and the plainer advice it was meant to replace.

What they did

Seventy-five adults meeting Rome III criteria for IBS were recruited from outpatient gastroenterology clinics in Sweden and randomised to one of two diets for four weeks. Thirty-eight were assigned to a diet low in FODMAPs (fermentable oligo-, di-, monosaccharides and polyols). Thirty-seven were assigned to what the authors call traditional IBS dietary advice: regular meal timing, avoiding large meals, and cutting back on fat, insoluble fibre, caffeine and gas-producing foods such as beans, cabbage and onions. The emphasis in that second arm was on how and when to eat rather than on which foods to exclude.

The primary outcome was the IBS Symptom Severity Scale (IBS-SSS), with a reduction of at least 50 points from baseline counted as a response. Participants kept a four-day food diary before and at the end of the intervention so the investigators could check adherence. Patients knew which diet they were on; the design was single-blind, meaning the outcome assessors, not the participants, were kept unaware of allocation.

What they found

Sixty-seven of the 75 participants completed the study (33 on low FODMAP, 34 on traditional advice). Symptom severity dropped significantly within both groups over the four weeks (p < 0.0001 for each arm against its own baseline). The between-group comparison was flat: p = 0.62 for the change in IBS-SSS, and the responder rates of 50% (19 of 38) versus 46% (17 of 37) were statistically indistinguishable (p = 0.72). Food diaries suggested that both groups followed their assigned advice reasonably well. The authors concluded that the low FODMAP diet reduces IBS symptoms about as well as traditional advice does, and floated the idea that combining elements of the two approaches might do better still.

Two later syntheses help put that result in context. A 2018 meta-analysis of seven low FODMAP trials in 397 participants found the diet reduced global symptoms compared with control interventions (relative risk of symptoms persisting 0.69, 95% CI 0.54 to 0.88), but rated the overall quality of evidence as very low, and noted that the trials with the most rigorous comparison diets showed the smallest effects (PMID: 30046155). A 2022 network meta-analysis of 13 trials in 944 patients ranked low FODMAP first against habitual diet for global symptoms (RR 0.67, 95% CI 0.48 to 0.91), and found it beat British Dietetic Association/NICE-style advice specifically for bloating, but not clearly for other endpoints (PMID: 34376515).

Strengths

• A genuine active comparator. Many low FODMAP trials compare the diet with a habitual or deliberately high-FODMAP diet, which makes the restricted diet look better than it would against sensible general advice. This trial tested the question clinicians actually face.
• Randomised, multicentre, and registered (NCT02107625), with a validated symptom instrument and adherence checked by food diary.
• Completion was good: 67 of 75 (89%) finished, so attrition is unlikely to explain the result.
• The traditional-advice arm was a real intervention delivered with structure, not a no-treatment control.

Limitations

• Size. With roughly 35 per arm, the trial could only have detected a large difference between diets. A “no difference” finding here is not the same as evidence of equivalence; the confidence interval around the between-group difference is wide.
• Four weeks is short. Neither durability nor the reintroduction phase that is central to real-world low FODMAP practice was studied, a gap the 2022 network meta-analysis explicitly calls out (PMID: 34376515).
• Diet trials cannot blind participants. Expectations about the “famous” diet versus plain advice could cut either way, and the placebo response in IBS trials commonly runs around 30 to 40%, which is close to the responder rates seen in both arms.
• Participants were recruited from specialist clinics in one country, with dietitian-level support. Results may not transfer to primary care or to people following the diet from a website.
• The IBS-SSS is a patient-reported composite; a 50-point change is a conventional threshold rather than a validated marker of what matters to patients.

What it means

The reasonable takeaway is modest: for people with IBS, structured dietary change of either kind may help over a month, and this trial gives no reason to believe the low FODMAP diet is clearly superior to simpler, less restrictive advice. That matters because the low FODMAP diet is harder to follow, carries nutritional and social costs, and is meant to be a temporary elimination followed by reintroduction. The meta-analytic evidence suggests low FODMAP has a real edge over doing nothing in particular, and perhaps over standard advice for bloating specifically, but the quality of that evidence is rated very low and the best-controlled trials show the smallest effects.

What readers should not conclude is that the diets have been shown to be equivalent, that four weeks of results predict a year, or that either approach works for everyone; roughly half of participants in each arm did not meet the responder threshold. Anyone considering a restriction diet for IBS, particularly someone with a history of disordered eating or already limited intake, should discuss it with a clinician or registered dietitian before starting.

References

• Böhn L, Störsrud S, Liljebo T, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015. PMID: 26255043
• Dionne J, Ford AC, Yuan Y, et al. A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. Am J Gastroenterol. 2018. PMID: 30046155
• Black CJ, Staudacher HM, Ford AC Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2022. PMID: 34376515